NCT06733597 Femoral BMD Change Following Cemented or Cementless Total Knee Arthroplasty
| NCT ID | NCT06733597 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Wisconsin, Madison |
| Condition | Knee Arthropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-03-06 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-03-06 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine femur bone mineral density (BMD) change before and after surgery in patients receiving cemented or cementless total knee arthroplasty (TKA). performed with manual or robotic methods. 100 participants will be enrolled and can expect to be on study for up to 26 months.
Eligibility Criteria
Inclusion Criteria: * Patients age greater than or equal to 55 years undergoing TKA with no prior total joint arthroplasty on the surgical side * Normal BMD or osteopenia with Fracture Risk Assessment Tool (FRAX) not meeting Bone Health and Osteoporosis Foundation (BHOF) treatment recommendations, i.e., 10-year major osteoporotic fracture risk greater then or equal to 20 percent or hip fracture risk greater than or equal to 3 percent. Exclusion Criteria: * Known clinical osteoporosis defined as any one of the following: * Hip or spine T-score less than or equal to -2.5 * History of low trauma fracture after age 50 * FRAX fracture risk calculation greater than or equal to 20 percent for major osteoporotic fracture or greater than or equal to 3 percent for hip fracture * Prior or current use of osteoporosis medications * Current use of systemic glucocorticoids or bone-active medications * Rheumatoid arthritis * Laboratory abnormalities that in the opinion of study investigators may impact bone mineral density; including calcium, creatinine, albumin and parathyroid hormone (PTH) * 25(OH)D less than 20 ng/mL * Not suitable for study participation due to other reasons at the investigator's discretion
Contact & Investigator
Brian Nickel, MD
PRINCIPAL INVESTIGATOR
UW School of Medicine and Public Health
Frequently Asked Questions
Who can join the NCT06733597 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, studying Knee Arthropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06733597 currently recruiting?
Yes, NCT06733597 is actively recruiting participants. Contact the research team at uwocrp@aging.wisc.edu for enrollment information.
Where is the NCT06733597 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT06733597 clinical trial?
NCT06733597 is sponsored by University of Wisconsin, Madison. The principal investigator is Brian Nickel, MD at UW School of Medicine and Public Health. The trial plans to enroll 100 participants.